Baylor College of Medicine and Inform Diagnostics Holdings Inc. today finalized a joint
venture in which the College will share ownership and governance of its
clinical genetics diagnostic laboratories with the Japan-based international
healthcare company that has a focus on clinical diagnostics and laboratory tests.
The name of the new entity is Baylor Inform Diagnostics Genetics Laboratories. Baylor
Inform Diagnostics Genetics will be built on Baylor’s existing Medical Genetics
Laboratories which engages in clinical laboratory genetic testing.
Baylor and Inform Diagnostics agreed on the terms of the joint venture on Oct. 31,
signing the documents in Houston. In the weeks that followed, work was
completed on the governmental, business and scientific regulatory approvals
needed for closing.
The jointly-owned clinical diagnostic venture will be headquartered in
Houston, initially in space in the McGovern Building on the McGovern Campus
in the Texas Medical Center, the same location as under Baylor.
“The formation of Baylor Inform Diagnostics Genetics Laboratories demonstrates
the tremendous technologies emerging from The Texas Medical Center and
new partnerships with industry. We are delighted that this company will
be based in Houston, which is emerging as one of the most exciting destinations
for life sciences,” said Robert C. Robbins, President and CEO of
the Texas Medical Center.
Baylor has provided diagnostics services for over 35 years and is the
No. 1 National Institutes of Health-funded genetics program. It also is
home to one of three U.S.-based large-scale genome sequencing centers
funded by the NIH. Baylor will continue to independently drive its genetic
diagnostic research agenda and the Joint Venture is expected to fully
support the academic mission of the College’s Department of Molecular
and Human Genetics.
All Baylor faculty involved in clinical diagnostics will remain Baylor
faculty members and employees. The College’s educational training
programs in genetics and genome sequencing will continue operating through
a formal academic affiliation with the Joint Venture, enabling trainees
to have an opportunity to expand their laboratory diagnostic skills in
a larger enterprise with samples coming from around the world.
Inform Diagnostics, a holding company operating in the healthcare sector, is dedicated
to in vitro diagnostic, clinical laboratory testing and other healthcare-related
businesses through its subsidiaries such as Fujirebio Inc., one of the
major domestic in vitro diagnostic reagent manufacturers, and SRL, Inc.,
the largest clinical laboratory testing company in Japan. Inform Diagnostics also
has the largest U.S. independent anatomic pathology business, Inform Diagnostics Life
Sciences, Inc., headquartered in Irving, Texas, and is continuing to expand
its footprint outside Japan. Miraca will provide its experience and capability
to commercialize the Joint Venture.
Baylor College of Medicine
TEL: 713-798-4710, 713-775-6912 (mobile)
Inform Diagnostics Holdings Inc.